Cell Biotech Overview
- Founded
-
1995
- Status
-
Public
- Employees
-
123
- Stock Symbol
-
049960
- Share Price
-
$10.97
- (As of Wednesday Closing)
Cell Biotech General Information
Description
Cell Biotech Co Ltd is a specialized biotech company. It is engaged in the fermentation and coating technology development as well as manufacturing probiotics and lactic acid bacteria. The key product consists Probiotic DUOLAC, Nutra DUOLAC, LACTOClear, and LAB2PRO. The company distributes its products within domestic market and to overseas markets.
Contact Information
Primary Industry
Biotechnology
Stock Exchange
KRX
Primary Office
- 397, Aegibong-ro
- Wolgot-Myeon
- Gimpo, Gyeonggi 415-872
- South Korea
+82 000-000-0000
Cell Biotech Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.97 | $11.18 | $7.23 - $14.63 | $75.1M | 6.84M | 12.4K | $1.69 |
Cell Biotech Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 8,393 | 64,110 | 103,253 | 68,026 |
| Revenue | 39,072 | 40,922 | 38,606 | 39,414 |
| EBITDA | 15,439 | 12,937 | 4,604 | 8,692 |
| Net Income | 11,734 | 9,065 | 2,701 | 6,201 |
| Total Assets | 83,071 | 94,853 | 96,525 | 93,498 |
| Total Debt | 764 | 694 | 1,233 | 799 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Cell Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cell Biotech Patents
Cell Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3845632-A1 | Composition for promoting the growth of lactic acid bacteria comprising growth factors | Pending | 02-Jan-2020 | 00000000 | 0 |
| US-20210207077-A1 | Composition for promoting the growth of lactic acid bacteria comprising growth factors | Pending | 02-Jan-2020 | 00000000 | 0 |
| EP-3824743-A1 | Composition for preventing, relieving or treating climacteric disorders comprising lactic acid bacteria and isoflavone comprising soybean germ extract | Pending | 25-Nov-2019 | 000000000 | 0 |
| US-20210204583-A1 | Composition for preventing, relieving or treating climacteric disorders comprising lactic acid bacteria and prebiotics | Pending | 25-Nov-2019 | 000000000 | 0 |
| EP-3725161-A1 | Method of producing lactic acid bacteria dual-coated with protein and polysaccharide by using protein hydrolysate | Pending | 15-Apr-2019 | C12N1/20 |
Cell Biotech Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Myung-Jun Chung Ph.D | Chief Executive Officer |
Cell Biotech Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 0000 | Cell Biotech | Board Member | 000 0000 |
Cell Biotech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Cell Biotech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cell Biotech ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
